持田製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4534/E00947 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2020/01/17 | 日証協 | 114,930株 | +7.18% | 41,703株 | +0.56% | 164,351株 | +1.88% | 52,362株 | -9.1% |
2020/01/10 | 日証協 | 107,230株 | -10.22% | 41,472株 | +702.17% | 161,321株 | +6.91% | 57,602株 | +638.49% |
2019/12/30 | 日証協 | 119,430株 | +3.02% | 5,170株 | -92.32% | 150,896株 | +0.27% | 7,800株 | -79.07% |
2019/12/27 | 日証協 | 115,930株 | +0.43% | 67,361株 | -23.66% | 150,496株 | +5.51% | 37,270株 | -39.86% |
2019/12/20 | 日証協 | 115,434株 | -16.79% | 88,242株 | -5.81% | 142,632株 | -8.29% | 61,968株 | -20.64% |
2019/12/13 | 日証協 | 138,721株 | -6.67% | 93,686株 | -18.23% | 155,519株 | +2.31% | 78,081株 | +63.48% |
2019/12/06 | 日証協 | 148,634株 | +17.73% | 114,568株 | +527.43% | 152,002株 | +5.3% | 47,763株 | +72.74% |
2019/11/29 | 日証協 | 126,248株 | -9.21% | 18,260株 | -54.94% | 144,353株 | -8.47% | 27,650株 | -30.7% |
2019/11/22 | 日証協 | 139,055株 | -9.09% | 40,520株 | +4.54% | 157,710株 | -5.51% | 39,900株 | +193.38% |
2019/11/15 | 日証協 | 152,955株 | -4.02% | 38,760株 | +61.3% | 166,910株 | -11.74% | 13,600株 | -53.85% |
2019/11/08 | 日証協 | 159,355株 | -7.29% | 24,030株 | +72.95% | 189,110株 | -14.7% | 29,467株 | -20.86% |
2019/11/01 | 日証協 | 171,888株 | -3.48% | 13,894株 | -64.34% | 221,706株 | -16.53% | 37,232株 | +109.5% |
2019/10/25 | 日証協 | 178,093株 | +43.06% | 38,967株 | -43.55% | 265,614株 | +27.59% | 17,772株 | -87.45% |
2019/10/18 | 日証協 | 124,491株 | -32.92% | 69,028株 | -61.44% | 208,184株 | +2.38% | 141,630株 | +208.36% |
2019/10/11 | 日証協 | 185,595株 | +78.56% | 179,037株 | +87.21% | 203,342株 | +0.77% | 45,930株 | -24.64% |
2019/10/04 | 日証協 | 103,937株 | +132.53% | 95,632株 | +136.7% | 201,784株 | +8.68% | 60,944株 | -44.39% |
2019/09/27 | 日証協 | 44,699株 | -77.67% | 40,402株 | -26.46% | 185,666株 | -16.5% | 109,598株 | +405.01% |
2019/09/20 | 日証協 | 200,145株 | +9.86% | 54,937株 | +36.23% | 222,354株 | -11.5% | 21,702株 | -46.39% |
2019/09/13 | 日証協 | 182,176株 | +0.01% | 40,326株 | -42.64% | 251,254株 | -18.76% | 40,478株 | +7.65% |
※株式分割は考慮していませんのでご注意ください。
Page Top